Evidence map›Paper›PMID 39560289›Full record

ArticleThe Laryngoscope2025

Prevalence of Molecular Diagnoses for Usher Syndrome and the Need for Coordinated Care.

Brett M Colbert, Molly Smeal, Zachary J Cromar, Potyra Rosa, Susan H Blanton, Byron L Lam, Xue Z Liu

Abstract read
In one paragraph

Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. A Genomic Analysis of Usher Syndrome: Population-Scale Prevalence and Therapeutic Targets.American journal of medical genetics. Part C, Seminars in medical genetics · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brett M Colbert *Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
Molly Smeal *Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
Zachary J Cromar *Dr. John T. Macdonald Foundation Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
Potyra RosaBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
Susan H BlantonDr. John T. Macdonald Foundation Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
Byron L LamBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
Xue Z LiuDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.ORCID 0000-0002-4758-6470

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2M
Molecular Genetics on Non Syndromic Hearing Loss (NSHL)R01DC005575 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, XUE Z · 2001 to 2024
$10.6M
Preclinical Testing of PI3K Inhibitors for Vestibular SchwannomasR01DC017264 · NIDCD · UNIVERSITY OF CENTRAL FLORIDA · PI FERNANDEZ-VALLE, CRISTINA MARIA, LIU, XUE Z · 2018 to 2022
$3.1M
Miami Otolaryngology Surgeon-Scientist Training Program (MOSSTP)R25DC020726 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Christine Thuyvan Dinh · 2023 to 2026
$988k
Development of human inner ear organoid platforms for human auditory/vestibular disordersR01DC022239 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, XUE Z · 2025 to 2025
$767k
NEI NIH HHS P30 EY014801NEI NIH HHS P30EY014801NIDCD NIH HHS R01 DC005575NIDCD NIH HHS R01DC005575NIDCD NIH HHS R01 DC017264NIDCD NIH HHS R01DC017264NIDCD NIH HHS R01 DC022239NIDCD NIH HHS R01DC022239NIDCD NIH HHS R25 DC020726NIDCD NIH HHS R25DC020726Research to Prevent Blindness-Unrestricted Grant GR004596
6 · The paper itself

Abstract

introductionUsher syndrome (USH) is a rare, autosomal-recessive genetic disorder and a leading cause of early onset deaf-blindness. A clinical diagnosis is made by the presence of retinitis pigmentosa (RP) with sensorineural hearing loss (SNHL). Subtype (USH1, USH2, USH3) is determined by severity and age of onset. Molecular testing is able to further distinguish USH subtypes by causative gene. As gene therapy strategies continue to be explored for USH, it is important to know the underlying genetic cause and to coordinate care among an interdisciplinary team.

methodsWe reviewed charts of 198 individuals presenting to the RP clinic at Bascom Palmer Eye Institute (BPEI) for suspected USH. Demographic information, USH clinical diagnosis, molecular testing, molecular diagnosis, and audiological data were collected.

resultsOf the 198 patients reviewed, 190 (96%) met clinical criteria for USH and received a clinical diagnosis. There were 67 (35%) that had a genetic test with a pathogenic molecular diagnosis. The average ages at molecular diagnosis were USH1B, 20 years old; USH2A, 37 years old; USH2C, 50 years old. Of the 67 with a molecular diagnosis, 23 (34%) established ophthalmic care and 8 of these (11%) established audiological care. DISCUSSION/

conclusionMolecular testing and diagnosis should be part of the routine care of USH individuals to facilitate earlier interventions and coordinated care between ophthalmology and audiology. LEVEL OF EVIDENCE: 4 Laryngoscope, 135:1777-1780, 2025.

Indexed as

Genetic TestingMolecular Diagnostic TechniquesUsher SyndromesAdolescentAdultAgedChildChild, PreschoolExtracellular Matrix ProteinsFemaleHumansMaleMiddle AgedPrevalenceRetrospective StudiesYoung AdultExtracellular Matrix ProteinsUSH2A protein, humanCoordinated careMolecular diagnosisRetinitis pigmentosaSensorineural hearing lossUsher syndrome

Identifiers

PMID39560289
PMCPMC11980960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.